Last reviewed · How we verify
Pemetrexed plus carboplatin combined with gefitinib
Pemetrexed plus carboplatin combined with gefitinib is a Small molecule drug developed by Shanghai Chest Hospital. It is currently in Phase 2 development. Also known as: Combination of chemotherapy and EGFR TKI.
At a glance
| Generic name | Pemetrexed plus carboplatin combined with gefitinib |
|---|---|
| Also known as | Combination of chemotherapy and EGFR TKI |
| Sponsor | Shanghai Chest Hospital |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Fatigue
- Constipation
- Decreased appetite
- Alopecia
- Diarrhoea
- Nausea
- Cough
- Rash
- Arthralgia
- Anaemia
- Thrombocytopenia
- Abdominal pain
Key clinical trials
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (PHASE2)
- Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma (NA)
- A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) (PHASE1, PHASE2)
- Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) (PHASE1, PHASE2)
- Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance (PHASE2)
- Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial (PHASE2)
- Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance (PHASE2)
- Combination of Chemotherapy and Gefitinib as First-line Treatment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pemetrexed plus carboplatin combined with gefitinib CI brief — competitive landscape report
- Pemetrexed plus carboplatin combined with gefitinib updates RSS · CI watch RSS
- Shanghai Chest Hospital portfolio CI
Frequently asked questions about Pemetrexed plus carboplatin combined with gefitinib
What is Pemetrexed plus carboplatin combined with gefitinib?
Pemetrexed plus carboplatin combined with gefitinib is a Small molecule drug developed by Shanghai Chest Hospital.
Who makes Pemetrexed plus carboplatin combined with gefitinib?
Pemetrexed plus carboplatin combined with gefitinib is developed by Shanghai Chest Hospital (see full Shanghai Chest Hospital pipeline at /company/shanghai-chest-hospital).
Is Pemetrexed plus carboplatin combined with gefitinib also known as anything else?
Pemetrexed plus carboplatin combined with gefitinib is also known as Combination of chemotherapy and EGFR TKI.
What development phase is Pemetrexed plus carboplatin combined with gefitinib in?
Pemetrexed plus carboplatin combined with gefitinib is in Phase 2.
What are the side effects of Pemetrexed plus carboplatin combined with gefitinib?
Common side effects of Pemetrexed plus carboplatin combined with gefitinib include Fatigue, Constipation, Decreased appetite, Alopecia, Diarrhoea, Nausea.
Related
- Manufacturer: Shanghai Chest Hospital — full pipeline
- Also known as: Combination of chemotherapy and EGFR TKI